An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine

Allergan

Status: Completed

Conditions: Migraine Disorders

Treatments: Drug: botulinum toxin Type A

Study type: Observational

Funder types: Industry

Identifiers

NCT01686581

MAF/AGN/NS/CM/002

Details and patient eligibility

About

This is an observational study to describe the long term use of Onabotulinumtoxin A (BOTOX®) as prescribed by the physician for headache prophylaxis in adults with chronic migraine. All treatment decisions lie with the physician.

Enrollment: 641 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prescribed BOTOX® for the prophylaxis of headaches.

Exclusion criteria

• Received treatment with any botulinum toxin Type A serotype in the last 26 weeks
• Current participation in Allergan's Botox Chronic Migraine Post-Authorisation Safety Study (protocol 191622-110).

Trial design

641 participants in 1 patient group

BOTOX®

Description:

BOTOX® (botulinum toxin Type A) administered according to physician prescription for the treatment of chronic migraine; all treatment decisions lie with the physician.

Treatment:

Drug: botulinum toxin Type A